News

News

VANCOUVER, British Columbia, September 18, 2023 -- Biocure Technology Inc. (“CURE” or the “Company”) (CSE: CURE) announces that it has entered into an exclusive letter agreement dated September 8, 2023 with Atriva Therapeutics GmbH. (“Atriva”) whereby the Company will acquire all of the issued and outstanding securities of Atriva (the “Transaction”). The Transaction will be a business combination completed by way of a share exchange, share purchase, amalgamation, arrangement, takeover bid, or other similar form of transaction.

Upon the successful completion of the proposed Transaction, it is anticipated that the Company will carry on the business of Atriva (the “Resulting Issuer”). The Transaction constitutes a ‘reverse takeover’ of the Company.

News

VANCOUVER, British Columbia, September 8, 2023 -- Biocure Technology Inc. (“CURE” or the “Company”) (CSE:CURE) announces that Sang Mok Lee has resigned from CEO and the board of directors. The Company would like to thank Mr. Lee for his contributions to the Company and wish him all the best for the future.

The Company is also pleased to announce that Yee Sing (Simon) Cheng has been appointed as CEO and the board of directors. Simon Cheng has over 10 years of experience of innovation and success in the technology and finance sector. His focus is on program development, with an emphasis on capital finance, business agreement negotiations and corporate development. He previously held positions with professional investment firms providing advisory services to high net worth individuals and institutional investors.

News

VANCOUVER, British Columbia, June 30, 2023 -- Biocure Technology Inc. (“Biocure” or the “Company”) (CSE:CURE) announces it intends to amend the terms of 6,706,525 share purchase warrants originally issued on July 14, 2021, as part of a private placement (the “Warrants”). The Warrants expire on July 14, 2023.

The Company wishes to extend the warrant term to July 14, 2026 and reduce the exercise price of the Warrants from $0.21 to $0.05 subject to the approval of the Canadian Securities Exchange and the consent of each of the holders of the Warrants. The amendment will require the incorporation of an accelerated expiry provision such that the remaining exercise period of the warrants will be reduced to 30 days if, for any 10 consecutive trading days during the unexpired term of such of the warrants, the closing price of the corporation's common shares exceeds the amended exercise price by 25% or more (which would be a trading price of $0.625 per common share or higher), with the 30-day expiry period commencing on the day the corporation disseminates a press release advising of the commencement of the exercise period.

News

VANCOUVER, British Columbia, June 1, 2023 -- Biocure Technology Inc. (“Biocure” or the “Company”) (CSE:CURE) announces today, further to its press releases dated December 19, 2022, that it has executed an agreement dated December 16, 2022, February 8, 2023, February 24, 2023 and May 18, 2023, the Company has the sale of 1,773,879 common shares and 57,954 preferred shares of BiocurePharm Corporation (“BPK”) held by the Company to CEO, Dr. Sang Mok Lee and the cancellation of an aggregate of 27,317,506 common shares of the Company held by Dr. Lee as consideration for the BPK securities (the “Transaction”). Following completion of the Transaction, the Company now has 81,603,652 common shares outstanding and Dr. Lee now no longer holds any securities of the Company other than 1,000,000 stock options with an exercise price of $0.30 and an expiry date of February 16, 2024.

Dr. Lee will continue to remain as the Company’s CEO and a director pending the completion of certain post-closing filings in Korea.

News

VANCOUVER, British Columbia, May 16, 2023 -- Biocure Technology Inc. (“Biocure” or the “Company”) (CSE:CURE) the Company is providing this update on the status of the management cease trade order granted on May 2, 2023 (the “MCTO”) by its principal regulator, the British Columbia Securities Commission (the “BCSC”), under National Policy 12-203 – Management Cease Trade Orders ("NP 12-203"). The MCTO does not affect the ability of investors who are not insiders to trade in the securities of the Company.

The Company confirms that it has today filed its audited annual financial statements for the year ended December 31, 2022, and accompanying management’s discussion and analysis, annual information form and related certifications (, as required under applicable securities laws. The MCTO remains in effect until revoked by the BCSC which the Company expects will occur in the next few days.

News

VANCOUVER, British Columbia, February 17, 2023 -- Biocure Technology Inc. (“Biocure” or the “Company”) (CSE:CURE) announces today that, further to its press releases dated February 7, 2023 and December 19, 2022, the Company’s shareholders have approved the sale of 1,773,879 common shares and 57,954 preferred shares (the “Shares”) of BiocurePharm Corporation (“BPK”) held by the Company, representing 51% of the shares currently held and 46% of the outstanding shares of BPK (the “Transaction”)

An aggregate of 5,690,538 shares votes were cast representing 5.22% of the issued and outstanding shares of the Company all in favor of the Transaction.

Under the terms of the Transaction, Dr. Lee will transfer to the Company an aggregate of 27,317,506 common shares of Biocure held by him for cancellation and return to treasury in consideration for the BPK Shares.

News

VANCOUVER, British Columbia, February 8, 2023 -- Biocure Technology Inc. (“Biocure” or the “Company”) (CSE:CURE) announces today that it has executed an amendment agreement dated February 7, 2023  with Sang Mok Lee, President and CEO, regarding the sale of 1,773,879 common shares and 57,954 preferred shares of BiocurePharm Corporation (“BPK”) held by the Company, representing 51% of the shares currently held and 46% of the outstanding shares of BPK (the “Transaction”)

News

VANCOUVER, British Columbia, February 3, 2023 -- Biocure Technology Inc. (“Biocure” or the “Company”) (CSE:CURE) would like to provide the following clarifications to the market and its stakeholders.

BiocurePharm Corporation (“BPK”), a subsidiary of Biocure Technology, has neither direct discussion nor relationship with Cigalah Healthcare in the Kingdom of Saudi Arabia.   BPK has formed an alliance with a Korean-based RIHU Healthcare and both parties are in the discussion about potential Biopharmaceutical business opportunities.

News

VANCOUVER, British Columbia, January 31, 2023 -- Biocure Technology Inc. (“CURE” or the “Company”) (CSE:CURE) BiocurePharm, Korea (“BPK”), a subsidiary of Biocure Technology Inc. (“CURE”) is pleased to announce that it has closed its non-brokered private placement through its Korean Subsidiary BiocurePharm, Korea (“BPK”), BPK has issued 55,000 shares at $4.32 CAD per share for gross proceeds of 220,000,000 KRW equivalent to $237,600 CAD.  All dollar values are based on the published Exchange Rate of CAD 0.001080 / KRW1 on January 27, 2023, Bank of Canada. After the issuance of new BPK shares, CURE holds now 92.10 % interest in BPK.

The net proceeds from the non-brokered private placement are intended to be used for general working capital.

News

VANCOUVER, British Columbia, January 20, 2023 -- Biocure Technology Inc. (“Biocure” or the “Company”) (CSE:CURE) is pleased to provide the following operational and investment update to the market and its stakeholders.

The Company plans to hold a special meeting for the purpose of considering the restructuring transaction, whereby Sang Mok Lee, President and CEO, will acquire 1,773,879 common shares and 57,954 preferred shares of BiocurePharm Corporation (“BPK”) held by the Company, representing 51% of the shares currently held and 46% of the outstanding shares of BPK (the “Transaction”). The Transaction is subject to the approval of at least 66 2/3% of the shareholders of the Company, voting in person or by proxy, in accordance with the requirements of the Business Corporations Act (British Columbia). The restructuring Transaction is designed to enable BPK, under the leadership of its CEO to separately market, finance and develop its product portfolio while the Company maintains a minority investment in BPK.

BiocurePharm Corporation (“BPK”), a subsidiary of the Company, has formed an alliance with a Korean-based RIHU Healthcare and the discussion is currently under way to produce Biosimilars and CD19 CAR-T in Kingdom of Saudi Arabia, where RIHU Healthcare has entered into a non-binding MOU with Cigalah Healthcare in Kingdom of Saudi Arabia.   

News

VANCOUVER, British Columbia, January 17, 2023 -- Biocure Technology Inc. (“CURE” or the “Company”) (CSE:CURE) BiocurePharm, Korea (“BPK”), a subsidiary of Biocure Technology Inc. (“CURE”) is pleased to announce that it has closed its non-brokered private placement through its Korean Subsidiary BiocurePharm, Korea (“BPK”), BPK has issued 12,500 shares at 4.328CAD per share for gross proceeds of $54,100.  All dollar values are based on the published Exchange Rate of CAD0.001082/KRW1 on January 13, 2023, Bank of Canada. After the issuance of new BPK shares, CURE holds now 93.42% interest in BPK.

The net proceeds from the non-brokered private placement are intended to be used for general working capital.

News

VANCOUVER, British Columbia, December 28, 2022 -- Biocure Technology Inc. (“CURE” or the “Company”) (CSE:CURE) BiocurePharm, Korea (“BPK”), a subsidiary of Biocure Technology Inc. (“CURE”) is pleased to announce that it has closed its non-brokered private placement through its Korean Subsidiary BiocurePharm, Korea (“BPK”), BPK has issued 16,250 shares at 4.248CAD per share for gross proceeds of $69,030. All dollar values are based on the published Exchange Rate of CAD0.001062/KRW1 on December 22, 2022, Bank of Canada. After the issuance of new BPK shares, CURE holds now 93.73% interest in BPK.

The net proceeds from the non-brokered private placement are intended to be used for general working capital.

News

VANCOUVER, British Columbia, December 21, 2022 -- Biocure Technology Inc. (“CURE” or the “Company”) (CSE:CURE) announces that Danny Joh has resigned from its board of directors. The Company would like to thank Mr. Joh for his contributions to the Company and wish him all the best for the future. The Company will be seeking for a suitable candidate to enhance the composition of the board of director.

Biocure Technology

Biocure Technology Inc.
300-1055 West Hastings Street
Vancouver, BC V6E 2E9

info@biocuretech.com
+1(604) 609-7146

© Biocure Technology Inc., all rights reserved

Search